IBX raises $6M in placement
Released
Released
Announcement PDF
®
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
23 November 2020
IBX raises $6M in placement
Highlights
• $6M raised in a heavily oversubscribed placement at 8.5c per share – a 6% discount to the 30-day
VWAP.
• Placement strongly supported by institutional investors.
• Additional capital supports IBX development of the MagSense™ HER2 breast cancer test for a
larger pivotal study including investing in manufacturing scale up.
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare
through the earlier detection of cancer, is pleased to announce it has raised $6M via a placement, at 8.5c
per share.
The placement, led by Evolution Capital Advisors, was cornerstoned by four Australian-based institutional
investors, and was met with very high demand.
The additional funds provide Imagion Biosystems with resources to accelerate its development plans and
begin investing in manufacturing scale up of its nanoparticle technology. The Company’s Phase I, first-inhuman study, for HER2 metastatic breast cancer is on schedule to commence this calendar quarter.
“With our first-in-human study on track to commence this quarter, this fund raise supports advancing the
next phase of product development and manufacturing scale up in parallel with the study rather than waiting
until the study is complete,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “This approach
will help shorten the timeline to commercial product.
“We are delighted by the high level of interest in IBX and the strength of support from investors for this
placement.”
The Company will issue 76,538,864 shares (including 6 million options to the Lead manager) under Listing
Rule 7.1, and 49,372 shares under Listing Rule 7.1A.
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases
earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian
Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Board of Directors of Imagion Biosystems Limited
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
®
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Australian Media & Investor Relations:
Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 (0) 401018828
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
Share your feedback
Discover